According to filings with the U.S. Securities and Exchange Commission, Intrommune Therapeutics is raising up to $10,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Michael Nelson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Intrommune Therapeutics
Intrommune Therapeutics, Inc. is a biotechnology company located in New York, NY. Intrommune is developing food allergy immunotherapies that are delivered while you brush your teeth, a lifelong habit that is ingrained in most people and ensures daily use of our product. Intrommunes elegant new treatment platform for food allergies is expected to be safe, effective and convenient. Intrommunes first product is a therapy for patients who suffer from peanut allergy. Intrommune is developing the oral mucosal immunotherapy (OMIT) platform for food allergies. It is a long-term solution for the 220 million, including 32 million people in the U.S., who suffer from this life-altering condition.

To learn more about Intrommune Therapeutics, visit http://intrommune.com/

Contact:
Michael Nelson, Chief Executive Officer
646-494-8432
https://www.linkedin.com/in/michael-nelson-ceo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.